Evidence map›Paper›PMID 35812398›Full record

ArticleFrontiers in immunology2022

Development and Verify of Survival Analysis Models for Chinese Patients With Systemic Lupus Erythematosus.

Linyu Geng, Wenqiang Qu, Jun Liang, Wei Kong, Xue Xu, Wenyou Pan, Lin Liu, Min Wu, Fuwan Ding, Huaixia Hu and 15 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Linyu GengDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Wenqiang QuSchool of Computer and Information, Hohai University, Nanjing, China.
Jun LiangDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Wei KongDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Xue XuDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Wenyou PanDepartment of Rheumatology, Huai'an First People's Hospital, Huai'an, China.
Lin LiuDepartment of Rheumatology, Xuzhou Central Hospital, Xuzhou, China.
Min WuDepartment of Rheumatology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Fuwan DingDepartment of Endocrinology, Yancheng Third People's Hospital, Yancheng, China.
Huaixia HuDepartment of Rheumatology, The Second People's Hospital of Lianyungang, Lianyungang, China.
Xiang DingDepartment of Rheumatology, The First People's Hospital of Lianyungang, Lianyungang, China.
Hua WeiDepartment of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou, China.
Yaohong ZouDepartment of Rheumatology, Wuxi People's Hospital, Wuxi, China.
Xian QianDepartment of Rheumatology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China.
Meimei WangDepartment of Rheumatology, Southeast University Zhongda Hospital, Nanjing, China.
Jian WuDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Juan TaoDepartment of Rheumatology, Wuxi TCM Hospital, Wuxi, China.
Jun TanDepartment of Rheumatology, Zhenjiang First People's Hospital, Zhenjiang, China.
Zhanyun DaDepartment of Rheumatology, Affiliated Hospital of Nantong University, Nantong, China.
Miaojia ZhangDepartment of Rheumatology, Jiangsu Province Hospital, Nanjing, China.
Jing LiDepartment of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Huayong ZhangDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Xuebing FengDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Jiaqi ChenSchool of Computer and Information, Hohai University, Nanjing, China.
Lingyun SunDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The aim of this study is to develop survival analysis models of hospitalized systemic lupus erythematosus (h-SLE) patients in Jiangsu province using data mining techniques to predict patient survival outcomes and survival status. Methods: In this study, based on 1999-2009 survival data of 2453 hospitalized SLE (h-SLE) patients in Jiangsu Province, we not only used the Cox proportional hazards model to analyze patients' survival factors, but also used neural network models to predict survival outcomes. We used semi-supervised learning to label the censored data and introduced cost-sensitivity to achieve data augmentation, addressing category imbalance and pseudo label credibility. In addition, the risk score model was developed by logistic regression. Results: The overall accuracy of the survival outcome prediction model exceeded 0.7, and the sensitivity was close to 0.8, and through the comparative analysis of multiple indicators, our model outperformed traditional classifiers. The developed survival risk assessment model based on logistic regression found that there was a clear threshold, i.e., a survival threshold indicating the survival risk of patients, and cardiopulmonary and neuropsychiatric involvement, abnormal blood urea nitrogen levels and alanine aminotransferase level had the greatest impact on patient survival time. In addition, the study developed a graphical user interface (GUI) integrating survival analysis models to assist physicians in diagnosis and treatment. Conclusions: The proposed survival analysis scheme identifies disease-related pathogenic and prognosis factors, and has the potential to improve the effectiveness of clinical interventions.

Indexed as

Lupus Erythematosus, SystemicChinaHumansProportional Hazards ModelsRisk FactorsSurvival Analysisdata miningneural networkregression modelsurvival analysissystemic lupus erythematosus

Identifiers

PMID35812398
PMCPMC9263294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.